Exploratory analyses from the MONALEESA-3 trial after more than 5 years of follow-up show that first-line use of ribociclib alongside fulvestrant continues to offers a significant overall survival benefit versus fulvestrant alone in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Adding the BCL2 inhibitor venetoclax to fulvestrant does not improve outcomes for women with estrogen receptor-positive, HER2-negative locally advanced breast cancer resistant to endocrine and CDK4/6 inhibitor treatment, say the VERONICA investigators.

The quality of life of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer remains largely unchanged by the addition of palbociclib to first-line fulvestrant, suggest data from the FLIPPER trial.

Adding alpelisib to fulvestrant improves overall survival in people with PIK3CA -mutated, hormone receptor-positive, HER2-negative advanced breast cancer, but not significantly so, show data from the phase 3 SOLAR-1 trial.

Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative, endocrine-sensitive, metastatic breast cancer, shows the phase 2 FLIPPER trial.

The combination of alpelisib and fulvestrant could be a promising option for patients with PIK3CA -mutated, hormone receptor-positive, HER2-negative advanced breast cancer who have progressed on prior CDK4/6 inhibitor and aromatase inhibitor treatment, indicate trial data.

Patients with hormone receptor-positive, HER2-negative metastatic breast cancer harboring PI3KCA mutations derive a significant progression-free survival benefit when fulvestrant is supplemented with the PI3K inhibitor alpelisib, phase III data show.

The efficacy of elacestrant was assessed in the phase 3 EMERALD trial , which demonstrated significantly longer progression-free survival for patients who received the SERD than for those given fulvestrant or an aromatase inhibitor.

The addition of the AKT inhibitor capivasertib to fulvestrant significantly prolongs the progression-free survival of people with hormone receptor-positive, HER2-negative advanced breast cancer that is resistant aromatase inhibitors, indicate the results of CAPItello-291.

Treatment with the novel oral selective estrogen receptor degrader camizestrant significantly improves progression-free survival versus fulvestrant in patients with pretreated, estrogen receptor-positive, HER2-negative advanced breast cancer, shows a phase 2 study.

Alpelisib in combination with fulvestrant is approved by the US FDA for men and postmenopausal women with hormone receptor-positive, HER2-negative, PIK3CA -mutated, advanced breast cancer that has progressed after prior endocrine therapy, explain the study authors in a research letter published in JAMA Oncology .

Adding capivasertib to fulvestrant significantly improves survival in patients with aromatase inhibitor resistant, estrogen receptor-positive, HER2-negative advanced breast cancer, particularly those with PIK3CA / AKT1 / PTEN alterations, FAKTION data show.

Patients previously treated with neither fulvestrant nor exemestane were given investigators’ choice of either of these drugs, but fulvestrant was encouraged.

The guideline makes no change to the first-line treatment option of trastuzumab, pertuzumab, plus a taxane, but recommends trastuzumab deruxtecan as a new second-line option and several new options in the third and later line, including regimens with tucatinib, trastuzumab emtansine, margetuximab, and abemaciclib plus trastuzumab and fulvestrant.

Women with hormone receptor-positive, HER2-negative metastatic breast cancer benefit from switching from an aromatase inhibitor to fulvestrant in palbociclib combination therapy when an ESR1 mutation is detected without disease progression, phase 3 PADA-1 trial data show.

Women with hormone receptor-positive, HER2-negative metastatic breast cancer benefit from switching from an aromatase inhibitor to fulvestrant in palbociclib combination therapy when an ESR1 mutation is detected without disease progression, phase 3 PADA-1 trial data show.

He added that standard single-agent endocrine therapy (eg, fulvestrant) in the second- and later-line is associated with a median PFS of around 2 months, and thus there is a “clinical unmet need for better endocrine therapy” for these patients.

The novel CDK4/6 inhibitor dalpiciclib plus fulvestrant could be “a new treatment option” for patients who have received prior endocrine therapy for hormone receptor-positive advanced breast cancer, say the DAWNA-1 investigators.

Supplementing fulvestrant with alpelisib does not adversely affect the health-related quality of life of patients with PIK3CA -mutated, hormone receptor-positive, HER2-negative, advanced breast cancer, indicate SOLAR-1 trial findings.